卢丽琴,赵同伟.胃癌术后辅助治疗的研究进展[J].肿瘤学杂志,2015,21(2):90-92.
胃癌术后辅助治疗的研究进展
Research Progress in Adjuvant Therapy for Postoperative Gastric Cancer
投稿时间:2014-06-04  
DOI:10.11735/j.issn.1671-170X.2015.02.B003
中文关键词:  胃肿瘤  辅助化疗  辅助放化疗  预后
英文关键词:gastric neoplasms  chemotherapy,adjuvant  chemoradiotherapy,adjuvant  prognosis
基金项目:
作者单位
卢丽琴 浙江省人民医院 
赵同伟 浙江省人民医院 
摘要点击次数: 2331
全文下载次数: 858
中文摘要:
      摘 要:胃癌发病率和死亡率一直居高不下。胃癌术后经常复发和远处转移,辅助治疗的价值已经没有争议。在亚洲,对于接受了标准D2手术的Ⅱ~Ⅲ期胃癌患者术后辅助化疗已经成为标准治疗,对于Ⅱ期患者口服S-1或XELOX联合化疗均可,而对于Ⅲb期及以上的高复发风险的胃癌患者应考虑使用XELOX方案化疗。在美国,采用D0和D1术比例较高,术后同步放化疗是目前适合的选择。欧美人群中,D2术式后采用辅助化疗还是辅助放化疗值得进一步研究。
英文摘要:
      Abstract:The morbidity and mortality of gastric cancer has been high worldwide. Recurrence and distant metastasis after gastric cancer surgery often occur and the value of adjuvant treatment has no dispute. In Asia,adjuvant chemotherapy has become the standard treatment for patients with gastric cancer stage Ⅱ~Ⅲ after standard D2 resection. Single agent S-1 or XELOX combined chemotherapy regimen is used for patients stage Ⅱ,while the XELOX combination regimen is optimal for the patients higher than or equal to stage Ⅲb. In USA,postoperative chemoradiotherapy seems reasonable choice,because patients with D0 and D1 resection account for high proportion. Adjuvant chemotherapy or chemoradiotherapy is optimal selection at present.
在线阅读   查看全文  查看/发表评论  下载PDF阅读器